Estradiol
Based on 124 publication(s) in Google Scholar
Estradiol (β-Estradiol) is a steroid hormone and the major female sex hormone. Estradiol can up-regulate the expression of neural markers of human endometrial stem cells (hEnSCs) and promote their neural differentiation. Estradiol can be used for the research of cancers, neurodegenerative diseases and neural tissue engineering.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.93%
- No. CAS: 50-28-2
- Fòrmula: C18H24O2
- Peso molecular:272.39
-
Almacenamiento:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
Publications Citing Use of MedChemExpress (MCE) Estradiol
More- Cell Metab. 2024 Nov 5;36(11):2402-2418.e10. [Abstract]
- Bioact Mater. 2025 Jul 15:53:240-252. [Abstract]
- Cancer Res. 2025 Nov 19. [Abstract]
- Nat Commun. 2025 Aug 22;16(1):7854. [Abstract]
- Bone Res. 2026 Mar 17;14(1):31. [Abstract]
- Nat Chem Biol. 2022 Nov;18(11):1196-1203. [Abstract]
- Neuro Oncol. 2024 Jan 5;26(1):137-152. [Abstract]
- Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
- J Adv Res. 2024 Dec 9:S2090-1232(24)00565-4. [Abstract]
- Engineering. 2025 Aug 27.
- Biosens Bioelectron. 2022 Nov 1:215:114548. [Abstract]
- Pharmacol Res. 2022 Mar:177:106050. [Abstract]
- ACS Cent Sci. 2026 Mar 25;12(4):497-523. [Abstract]
- Cell Death Dis. 2020 Oct 6;11(10):831. [Abstract]
- Genome Biol. 2025 May 9;26(1):124. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Aug 19;122(33):e2507571122. [Abstract]
- J Cachexia Sarcopenia Muscle. 2025 Apr;16(2):e13807. [Abstract]
- Proc Natl Acad Sci U S A. 2025 Mar 25;122(12):e2426107122. [Abstract]
- J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13693. [Abstract]
- Cell Commun Signal. 2019 Aug 14;17(1):94. [Abstract]
- Int J Biol Macromol. 2026 Mar:352:151224. [Abstract]
- Int J Biol Macromol. 2023 May 1:236:123987. [Abstract]
- Phytomedicine. 2025 Jun:141:156701. [Abstract]
- Phytomedicine. 2025 Mar:138:156429. [Abstract]
- Phytomedicine. 2024 Jul 25:130:155767. [Abstract]
- Phytomedicine. 2023 Jan:109:154593. [Abstract]
- Free Radic Biol Med. 2023 Feb 1:195:231-244. [Abstract]
- Chemosphere. 2024 Oct:366:143466. [Abstract]
- Sci Total Environ. 2024 Jul 6:947:174543. [Abstract]
- Sci Total Environ. 2024 May 25:173419. [Abstract]
- NPJ Breast Cancer. 2022 Mar 10;8(1):31. [Abstract]
- J Transl Med. 2025 Oct 17;23(1):1128. [Abstract]
- Biomed Pharmacother. 2024 Jun 3:176:116852. [Abstract]
- J Transl Med. 2024 Mar 9;22(1):255. [Abstract]
- Biomed Pharmacother. 2019 Aug:116:109001. [Abstract]
- Environ Pollut. 2022 Jan 1;292(Pt B):118370. [Abstract]
- Environ Pollut. 2021 Feb 1;270:116015. [Abstract]
- Aging Cell. 2026 Apr;25(4):e70463. [Abstract]
- Aging Cell. 2024 Aug 7:e14303. [Abstract]
- J Med Chem. 2025 Oct 15. [Abstract]
- J Med Chem. 2025 Jun 12;68(11):11127-11148. [Abstract]
- J Med Chem. 2025 Mar 27;68(6):6127-6148. [Abstract]
- Br J Cancer. 2022 Sep;127(5):927-936. [Abstract]
- J Med Chem. 2022 Mar 10;65(5):3894-3912. [Abstract]
- Anal Chem. 2026 Jun 16;98(23):16962-16970. [Abstract]
- NPJ Regen Med. 2023 May 2;8(1):23. [Abstract]
- J Anim Sci Biotechnol. 2023 Jan 5;14(1):6. [Abstract]
- Mol Med. 2025 Feb 25;31(1):78. [Abstract]
- Phytother Res. 2025 May 8. [Abstract]
- Cell Mol Life Sci. 2024 Dec 27;82(1):17. [Abstract]
- Hum Reprod. 2025 Jul 29:deaf130. [Abstract]
- JCI Insight. 2024 Oct 31:e182418. [Abstract]
- Ecotoxicol Environ Saf. 2024 Jul 2:281:116680. [Abstract]
- Hum Reprod. 2019 May 1;34(5):804-812. [Abstract]
- Biochem Pharmacol. 2026 May:247:117796. [Abstract]
- Biochem Pharmacol. 2025 Oct 29;243(Pt 1):117481. [Abstract]
- Biochem Pharmacol. 2024 Dec;230(Pt 1):116564. [Abstract]
- Genome Res. 2024 May 15;34(4):539-555. [Abstract]
- Pain. 2021 Jun 1;162(6):1882-1896. [Abstract]
- J Ethnopharmacol. 2025 May 10:119968. [Abstract]
- J Ethnopharmacol. 2021 Jun 28:274:114064. [Abstract]
- Mol Ther Oncolytics. 2022 Aug 5:26:372-386. [Abstract]
- Cells. 2026 Jan 29;15(3):260. [Abstract]
- J Clin Endocrinol Metab. 2021 Apr 23;106(5):1410-1426. [Abstract]
- Inflammation. 2025 Aug 2. [Abstract]
- Biomed Signal Process Control. 2026 Feb 26.
- Int J Mol Sci. 2023 Apr 6;24(7):6826. [Abstract]
- Int Immunopharmacol. 2025 Aug 19:164:115392. [Abstract]
- Int Immunopharmacol. 2025 Jan 24:148:114104. [Abstract]
- Int Immunopharmacol. 2024 Nov 2;143(Pt 3):113527. [Abstract]
- Int Immunopharmacol. 2024 Sep 5;142(Pt A):113059. [Abstract]
- Eur J Pharmacol. 2022 May 15;923:174908. [Abstract]
- Int Immunopharmacol. 2020 Jan;78:105937. [Abstract]
- Neuropharmacology. 2024 Sep 5:110138. [Abstract]
- Molecules. 2022 Aug 6;27(15):5000. [Abstract]
- Cell Rep Methods. 2023 Oct 23;3(10):100599. [Abstract]
- Cancers (Basel). 2024 Feb 9;16(4):726. [Abstract]
- Poult Sci. 2025 May 3;104(7):105259. [Abstract]
- Biochim Biophys Acta Mol Basis Dis. 2024 Mar;1870(3):167011. [Abstract]
- J Cell Mol Med. 2020 Jan;24(2):1599-1613. [Abstract]
- Sci Rep. 2026 Apr 20;16(1):12890. [Abstract]
- Sci Rep. 2025 May 8;15(1):16053. [Abstract]
- Sci Rep. 2025 Mar 12;15(1):8531. [Abstract]
- Cell Signal. 2025 Sep 8:136:112121. [Abstract]
- Cell Signal. 2024 Aug 13:111346. [Abstract]
- Aquacult Rep. February 2022, 100930.
- Neurobiol Stress. 2020 Oct 14;13:100256. [Abstract]
- Mol Hum Reprod. 2025 Jul 3;31(3):gaaf037. [Abstract]
- Mol Med Rep. 2024 Jul;30(1):123. [Abstract]
- Food Chem Toxicol. 2023 Jun:176:113807. [Abstract]
- BMC Cancer. 2023 Oct 31;23(1):1047. [Abstract]
- Life Metab. 2023 Nov 6;3(1):load041. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Dec 18. [Abstract]
- Mol Reprod Dev. 2025 May;92(5):e70025. [Abstract]
- Genomics. 2025 Jan 21;117(2):111002. [Abstract]
- Breast Cancer Res Treat. 2023 Dec;202(3):595-606. [Abstract]
- Biol Reprod. 2022 Oct 11;107(4):1026-1034. [Abstract]
- J Pharmacol Sci. 2024 May;155(1):1-13. [Abstract]
- Genes (Basel). 2023 Jul 19;14(7):1466. [Abstract]
- Front Genet. 2022 Sep 20:13:992444. [Abstract]
- J Assist Reprod Genet. 2024 Nov;41(11):3189-3200. [Abstract]
- PLoS One. 2020 Oct 1;15(10):e0239659. [Abstract]
- J Steroid Biochem Mol Biol. 2025 Jun 2:106800. [Abstract]
- Fishes. 2023 Dec 19, 9(1), 1.
- Gene. 2023 Aug 30:879:147592. [Abstract]
- Fishes. 2022, 7(5), 223.
- Steroids. 2022 Dec:188:109114. [Abstract]
- Biochem Biophys Res Commun. 2025 Jun 14:776:152212. [Abstract]
- Biochem Biophys Res Commun. 2025 May 20:772:152050. [Abstract]
- Physiol Rep. 2024 Sep;12(17):e70047. [Abstract]
- Zygote. 2022 Jun;30(3):330-337. [Abstract]
- Patent. US20250320507A1.
- bioRxiv. 2025 Sep 12.
- SSRN. 2025 Jan 27.
- bioRxiv. 2024 August 04.
- SSRN. 2023 Nov 29.
- Research Square Preprint. 2023 Dec 2.
- bioRxiv. 2023 Nov 2:2023.10.30.564691. [Abstract]
- bioRxiv. 2023 Jul 27.
- Research Square Preprint. 2023 May 8.
- Harvard University. 2023 Mar. 30487357.
- Research Square Preprint. 2022 Jun.
- Research Square Preprint. 2022 Feb.
- Res Sq. 2020 Dec 31:rs.3.rs-100914. [Abstract]
-
WB
-
WB
-
WB
-
Cell Proliferation/Viability Assay
-
WB
Ver todos los productos específicos de isoformas Endogenous Metabolite
More
Actividad biológica
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16-F10 | IC50 |
39.81 μM
Compound: ES
|
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
Antiproliferative activity mouse B16F10 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| CHO | EC50 |
38.4 μM
Compound: 55
|
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
Agonist activity at human TGR5 expressed in CHO cells by luciferase assay
|
[PMID: 18307294] |
| CHO | IC50 |
>100 μM
Compound: ES
|
Antiproliferative activity against CHO cells after 2 days by MTT assay
Antiproliferative activity against CHO cells after 2 days by MTT assay
|
[PMID: 25222876] |
| CHO-K1 | EC50 |
0.03 μM
Compound: E2
|
Agonist activity at ERbeta expressed in CHO-K1 cells by luciferase reporter gene transactivation assay
Agonist activity at ERbeta expressed in CHO-K1 cells by luciferase reporter gene transactivation assay
|
[PMID: 20553023] |
| CHO-K1 | EC50 |
0.05 μM
Compound: E2
|
Agonist activity at ERalpha expressed in CHO-K1 cells by luciferase reporter gene transactivation assay
Agonist activity at ERalpha expressed in CHO-K1 cells by luciferase reporter gene transactivation assay
|
[PMID: 20553023] |
| CHO-K1 | EC50 |
0.036 nM
Compound: E2
|
Transcriptional activation of ERbeta receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay
Transcriptional activation of ERbeta receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay
|
[PMID: 22647217] |
| CHO-K1 | EC50 |
0.05 nM
Compound: E2
|
Transcriptional activation of ERalpha receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay
Transcriptional activation of ERalpha receptor expressed in CHO-K1 cells after 24 hrs by luciferase reporter gene assay
|
[PMID: 22647217] |
| COS-1 | EC50 |
2.4 nM
Compound: 1
|
In vitro agonist activity for estrogen receptor alpha expressed in COS-1 cells
In vitro agonist activity for estrogen receptor alpha expressed in COS-1 cells
|
[PMID: 15713407] |
| COS-1 | EC50 |
9.7 nM
Compound: 1
|
In vitro agonist activity for estrogen receptor beta expressed in COS-1 cells
In vitro agonist activity for estrogen receptor beta expressed in COS-1 cells
|
[PMID: 15713407] |
| COS-7 | EC50 |
0.3 nM
Compound: 17beta-estradiol
|
Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level by spectrofluorimetry
Agonist activity at GFP-tagged GPR30 expressed in COS7 cells assessed as half life for increase in intracellular calcium level by spectrofluorimetry
|
[PMID: 16520733] |
| COS-7 | EC50 |
11 nM
Compound: Estradiol
|
Agonist activity at estrogen receptor beta ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
Agonist activity at estrogen receptor beta ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
|
[PMID: 19863083] |
| COS-7 | EC50 |
3.2 nM
Compound: Estradiol
|
Agonist activity at estrogen receptor alpha ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
Agonist activity at estrogen receptor alpha ligand binding domain expressed in african green monkey COS7 cells co-transfected with Gal4-LBD by luciferase reporter gene assay
|
[PMID: 19863083] |
| HEC-1 | EC50 |
0.13 nM
Compound: estradiol
|
Agonist activity at full-length human estrogen receptor beta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
Agonist activity at full-length human estrogen receptor beta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
|
[PMID: 19128016] |
| HEC-1 | EC50 |
0.7 nM
Compound: estradiol
|
Agonist activity at full-length human estrogen receptor alpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
Agonist activity at full-length human estrogen receptor alpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
|
[PMID: 19128016] |
| HEC-1 | EC50 |
0.1 nM
Compound: estradiol
|
Agonist activity at ERalpha expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay
Agonist activity at ERalpha expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay
|
[PMID: 19286283] |
| HEC-1 | EC50 |
0.5 nM
Compound: estradiol
|
Agonist activity at ERbeta expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay
Agonist activity at ERbeta expressed in human HEC1 cells assessed as transcriptional potency after 24 hrs by luciferase-beta galactosidase reporter gene assay
|
[PMID: 19286283] |
| HEC-1 | EC50 |
0.09 nM
Compound: Estradiol
|
Agonist activity at human full-length ERalpha receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
Agonist activity at human full-length ERalpha receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
|
[PMID: 21481497] |
| HEC-1 | EC50 |
0.72 nM
Compound: Estradiol
|
Agonist activity at human full-length ERbeta receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
Agonist activity at human full-length ERbeta receptor expressed in human HEC1 cells co-expressing (ERE)2-pS2-luc gene assessed as transcriptional activation after 24 hrs by luciferase reporter gene assay
|
[PMID: 21481497] |
| HEC-1 | EC50 |
0.123 nM
Compound: E2, 17beta-E2, estradiol
|
Agonist activity at human ERalpha expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay
Agonist activity at human ERalpha expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay
|
[PMID: 22122563] |
| HEC-1 | EC50 |
0.2 nM
Compound: E2, 17beta-E2, estradiol
|
Agonist activity at human ERbeta expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay
Agonist activity at human ERbeta expressed in HEC-1 cells coexpressing beta-gal assessed as luciferase activity after 24 hrs by reporter gene assay
|
[PMID: 22122563] |
| HEC-1 | EC50 |
0.16 nM
Compound: estradiol
|
Agonist activity at human ERalpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay
Agonist activity at human ERalpha expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay
|
[PMID: 25559213] |
| HEC-1 | EC50 |
0.38 nM
Compound: estradiol
|
Agonist activity at human ERbeta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay
Agonist activity at human ERbeta expressed in human HEC1 cells assessed as transcriptional activation after 24 hrs by ERE-luciferase reporter gene transfection assay
|
[PMID: 25559213] |
| HEK293 | IC50 |
>30 μM
Compound: beta-Estradiol
|
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT2-expressing HEK293 cells
|
[PMID: 12110607] |
| HEK293 | IC50 |
2.88 μM
Compound: beta-Estradiol
|
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT3-expressing HEK293 cells
|
[PMID: 12110607] |
| HEK293 | IC50 |
5.73 μM
Compound: beta-Estradiol
|
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells
TP_TRANSPORTER: inhibition of MPP+ uptake (MPP+: 0.25 uM) in OCT1-expressing HEK293 cells
|
[PMID: 12110607] |
| HEK293 | EC50 |
0.75 nM
Compound: 17-beta-estradiol
|
Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERalpha
Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERalpha
|
[PMID: 16309907] |
| HEK293 | EC50 |
2.1 nM
Compound: 17-beta-estradiol
|
Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERbeta
Effect on transactivation of ALP gene expression in HEK293 cells transfected with hERbeta
|
[PMID: 16309907] |
| HEK293 | EC50 |
0.75 nM
Compound: estradiol
|
Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay
Agonist activity at human recombinant ERalpha expressed in HEK293 cells by transactivation assay
|
[PMID: 17448656] |
| HEK293 | EC50 |
2.1 nM
Compound: estradiol
|
Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay
Agonist activity at human recombinant ERbeta expressed in HEK293 cells by transactivation assay
|
[PMID: 17448656] |
| HEK293 | EC50 |
0.75 nM
Compound: estradiol
|
Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay
Agonist activity at ERalpha expressed in HEK293 cells by transactivation assay
|
[PMID: 17890084] |
| HEK293 | EC50 |
2.1 nM
Compound: estradiol
|
Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay
Agonist activity at ERbeta expressed in HEK293 cells by transactivation assay
|
[PMID: 17890084] |
| HEK293 | EC50 |
4.6 nM
Compound: E2
|
Agonist activity at ZFP-fused ERRbeta LBD expressed in HEK293 cells by TR-FRET assay
Agonist activity at ZFP-fused ERRbeta LBD expressed in HEK293 cells by TR-FRET assay
|
[PMID: 21218783] |
| HEK293 | EC50 |
0.046 nM
Compound: 1
|
Agonist activity at ERalpha expressed in HEK cells co-expressing beta-lactamase after 18 hrs by beta-lactamase reporter gene assay
Agonist activity at ERalpha expressed in HEK cells co-expressing beta-lactamase after 18 hrs by beta-lactamase reporter gene assay
|
[PMID: 21885279] |
| HEK293 | IC50 |
50 μM
Compound: Estradiol
|
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit
|
[PMID: 22761000] |
| HEK293 | EC50 |
0.024 nM
Compound: beta-Est
|
Agonist activity at human ERalpha expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at human ERalpha expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 25305688] |
| HEK293 | EC50 |
0.085 nM
Compound: beta-Est
|
Agonist activity at human ERbeta expressed in HEK293 cells by luciferase reporter gene assay
Agonist activity at human ERbeta expressed in HEK293 cells by luciferase reporter gene assay
|
[PMID: 25305688] |
| HEK293 | EC50 |
0.09 nM
Compound: E2
|
Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay
Selective estrogen receptor down-regulator activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ERalpha degradation by luciferase reporter gene assay
|
[PMID: 30940565] |
| HEK293 | EC50 |
0.13 nM
Compound: E2
|
Agonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
Agonist activity at FLAG-tagged ERalpha (unknown origin) expressed in HEK293 cells assessed as induction of ER-alpha-mediated transcriptional activity by luciferase reporter gene assay
|
[PMID: 30940565] |
| HEK-293T | EC50 |
10.4 nM
Compound: E2
|
Agonist activity at human ERbeta E305A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay
Agonist activity at human ERbeta E305A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay
|
[PMID: 20659801] |
| HEK-293T | EC50 |
2.5 nM
Compound: E2
|
Agonist activity at human ERalpha E353A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay
Agonist activity at human ERalpha E353A mutant expressed in HEK293T cells co-expressing ERE assessed as transactivation activity by luciferase reporter gene assay
|
[PMID: 20659801] |
| HeLa | EC50 |
0.02 nM
Compound: 17-beta-estradiol
|
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor alpha.
|
[PMID: 11906280] |
| HeLa | EC50 |
0.07 nM
Compound: 17-beta-estradiol
|
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.
Activation of estrogen response element in HeLa cells stably transfected with human Estrogen receptor beta.
|
[PMID: 11906280] |
| HeLa | IC50 |
24 nM
Compound: 1
|
Inhibition of [3H]estradiol binding to human estrogen receptor beta expressed in HeLa cells
Inhibition of [3H]estradiol binding to human estrogen receptor beta expressed in HeLa cells
|
[PMID: 15658851] |
| HeLa | IC50 |
28 nM
Compound: 1
|
Inhibition of [3H]estradiol binding to human estrogen receptor alpha expressed in HeLa cells
Inhibition of [3H]estradiol binding to human estrogen receptor alpha expressed in HeLa cells
|
[PMID: 15658851] |
| HeLa | EC50 |
0.59 nM
Compound: (+)-3,17-beta-estradiol
|
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay at 10 uM
|
[PMID: 16610787] |
| HeLa | EC50 |
0.84 nM
Compound: (+)-3,17-beta-estradiol
|
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay
Inhibition of ER beta-mediated transactivation of ERE in HeLa cell luciferase assay
|
[PMID: 16610787] |
| HeLa | EC50 |
0.21 nM
Compound: E2
|
Agonist activity at ERalpha (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay
Agonist activity at ERalpha (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay
|
[PMID: 31879182] |
| HeLa | EC50 |
0.37 nM
Compound: E2
|
Agonist activity at ERbeta (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay
Agonist activity at ERbeta (unknown origin) expressed in human HeLa cells assessed as transcriptional activation measured after 24 hrs by luciferase reporter gene assay
|
[PMID: 31879182] |
| HeLa | EC50 |
0.7 nM
Compound: 38
|
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells assessed as reduction in cell viability after 72 hrs by MTT assay
|
[PMID: 37077378] |
| Hepatocyte | EC50 |
1.9 μM
Compound: Estradiol
|
Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method
Induction of CYP2B6 mRNA expression in human donor hepatocytes after 48 hrs by real-time PCR method
|
[PMID: 22815312] |
| Hepatocyte | EC50 |
4.1 μM
Compound: Estradiol
|
Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method
Induction of CYP2B6 activity in human donor hepatocytes assessed as hydroxybupropion formation after 48 hrs by LC/MS method
|
[PMID: 22815312] |
| HepG2 | EC50 |
11 nM
Compound: E2, estradiol
|
Agonist activity at human ERbeta expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay
Agonist activity at human ERbeta expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay
|
[PMID: 22283328] |
| HepG2 | EC50 |
2.2 nM
Compound: E2, estradiol
|
Agonist activity at human ERalpha expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay
Agonist activity at human ERalpha expressed in HepG2 cells after 24 hrs by luciferase reporter gene assay
|
[PMID: 22283328] |
| HRPE | IC50 |
1.1 μM
Compound: beta-Estradiol
|
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT3-expressing HRPE cells
|
[PMID: 9830022] |
| HRPE | IC50 |
84.8 μM
Compound: beta-Estradiol
|
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells
TP_TRANSPORTER: inhibition of TEA uptake (TEA: 20 uM) in OCT2-expressing HRPE cells
|
[PMID: 9830022] |
| Ishikawa | EC50 |
0.047 nM
Compound: 17-beta-estradiol
|
Estrogenic activity at estrogen receptor in human Ishikawa Var-1 cells assessed as stimulation of alkaline phosphatase activity measured by metabolism of p-nitrophenol phosphatase after 72 hrs
Estrogenic activity at estrogen receptor in human Ishikawa Var-1 cells assessed as stimulation of alkaline phosphatase activity measured by metabolism of p-nitrophenol phosphatase after 72 hrs
|
[PMID: 15568770] |
| Ishikawa | EC50 |
0.9 nM
Compound: E2
|
Agonist activity at estrogen receptor in human Ishikawa cells assessed as increase of alkaline phosphatase level after 3 days using P-nitrophenyl phosphate as substrate
Agonist activity at estrogen receptor in human Ishikawa cells assessed as increase of alkaline phosphatase level after 3 days using P-nitrophenyl phosphate as substrate
|
[PMID: 22178552] |
| Ishikawa | EC50 |
24.6 pM
Compound: E2
|
Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression after 72 hrs by microplate reader
Estrogenic activity at estrogen receptor in human Ishikawa cells assessed as induction of alkaline phosphatase expression after 72 hrs by microplate reader
|
[PMID: 22464681] |
| Ishikawa | EC50 |
0.01 nM
Compound: 1
|
Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
Concentration of compound required to induce 50 % of the maximum stimulation of alkaline phosphatase activity in Ishikawa cells
|
[PMID: 8201587] |
| JEG-3 | IC50 |
84 μM
Compound: 17-a Estradiol
|
Inhibition of steroid sulfatase activity of JEG-3 cells
Inhibition of steroid sulfatase activity of JEG-3 cells
|
[PMID: 11087571] |
| JEG-3 | IC50 |
84 μM
Compound: 3
|
Estrone sulfatase activity against homogenized human JEG-3 cells was determined by measuring the [3H]E1 obtained from [3H]E1S
Estrone sulfatase activity against homogenized human JEG-3 cells was determined by measuring the [3H]E1 obtained from [3H]E1S
|
[PMID: 9873454] |
| MCF7 | EC50 |
0.007 nM
Compound: 17-beta-estradiol
|
Agonist effect on transcriptional activation in MCF-7 cells expressing estrogen receptor alpha
Agonist effect on transcriptional activation in MCF-7 cells expressing estrogen receptor alpha
|
[PMID: 10673099] |
| MCF7 | IC50 |
32 μM
Compound: estradiol
|
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
Inhibitory concentration against MCF-7 (ER+) cell line using SRB assay
|
[PMID: 12565971] |
| MCF7 | EC50 |
0.01 nM
Compound: 4 (estradiol (E2))
|
Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells
Percent agonistic activity for estrogen-induced pS2 expression in MCF-7 cells
|
[PMID: 12749898] |
| MCF7 | ED50 |
0.00456 nM
Compound: 2
|
Functional ERalpha receptor activity in transcriptional activation assay in MCF-7 cells
Functional ERalpha receptor activity in transcriptional activation assay in MCF-7 cells
|
[PMID: 12824043] |
| MCF7 | EC50 |
0.01 nM
Compound: 1 (17-beta-estradiol)
|
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
Effective concentration against MCF-7 breast tumor cells using MCF-7 assay.
|
[PMID: 12825935] |
| MCF7 | IC50 |
3 nM
Compound: estradiol
|
Displacement of [3H]estradiol from Estrogen receptor in MCF-7 cells
Displacement of [3H]estradiol from Estrogen receptor in MCF-7 cells
|
[PMID: 1548683] |
| MCF7 | EC50 |
8.0 x 10-11 M
Compound: estradiol
|
Effective concentration against human ER positive MCF-7 breast cancer cell line evaluated by luciferase assay
Effective concentration against human ER positive MCF-7 breast cancer cell line evaluated by luciferase assay
|
[PMID: 16190777] |
| MCF7 | EC50 |
0.01 nM
Compound: 1
|
Effect on ERalpha in MCF7 cell line transfected with ER responsive luciferase reporter
Effect on ERalpha in MCF7 cell line transfected with ER responsive luciferase reporter
|
[PMID: 16219463] |
| MCF7 | IC50 |
0.4 nM
Compound: estrogen
|
Inhibition of chemoattractant-induced cell migration of human MCF7 cells after 48 hrs by transwell migration assay
Inhibition of chemoattractant-induced cell migration of human MCF7 cells after 48 hrs by transwell migration assay
|
[PMID: 16520733] |
| MCF7 | EC50 |
3.7 x 10-12 M
Compound: estradiol
|
Estrogenic activity in human MCF7 cells assessed as cell proliferation after 6 days by WST8 assay
Estrogenic activity in human MCF7 cells assessed as cell proliferation after 6 days by WST8 assay
|
[PMID: 18760603] |
| MCF7 | EC50 |
10 nM
Compound: E2
|
Agonist activity at human ERalpha LBD in human MCF7 cells assessed as induction of cell proliferation after up to 6 days by celltiter-glo assay
Agonist activity at human ERalpha LBD in human MCF7 cells assessed as induction of cell proliferation after up to 6 days by celltiter-glo assay
|
[PMID: 21218783] |
| MCF7 | EC50 |
6.4 pM
Compound: E2
|
Antiproliferative activity against estrogen-deficient human MCF7 cells after 72 hrs by MTT assay
Antiproliferative activity against estrogen-deficient human MCF7 cells after 72 hrs by MTT assay
|
[PMID: 22464681] |
| MCF7 | IC50 |
27.35 μM
Compound: ES
|
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
Antiproliferative activity human ER-positive MCF7 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| MCF7 | EC50 |
0.0084 nM
Compound: estradiol
|
Agonist activity at human ERalpha in human MCF7 cells assessed as progesterone receptor endogenous genes activation after 24 hrs by qPCR
Agonist activity at human ERalpha in human MCF7 cells assessed as progesterone receptor endogenous genes activation after 24 hrs by qPCR
|
[PMID: 25559213] |
| MCF7 | EC50 |
0.3 nM
Compound: estradiol
|
Agonist activity at human ERbeta in human MCF7 cells assessed as otubain 2 endogenous genes activation after 24 hrs by qPCR
Agonist activity at human ERbeta in human MCF7 cells assessed as otubain 2 endogenous genes activation after 24 hrs by qPCR
|
[PMID: 25559213] |
| MCF7 | EC50 |
0.02 nM
Compound: E2
|
Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
Effective dose for [3H]- estradiol against proliferation of MCF-7 cells
|
[PMID: 2769681] |
| MCF7 | EC50 |
0.996 x 10-10 M
Compound: estradiol
|
Affinity estrogen receptor of MCF-7 human mammary cancer cells
Affinity estrogen receptor of MCF-7 human mammary cancer cells
|
[PMID: 8627615] |
| MCF7 | EC50 |
0.292 nM
Compound: estradiol
|
Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells
Induction of pS2 mRNA expression in human MCF-7 mammary carcinoma cells
|
[PMID: 8627615] |
| MCF7 | EC50 |
0.7 nM
Compound: estradiol
|
Stimulation of MCF-7 cell proliferation
Stimulation of MCF-7 cell proliferation
|
[PMID: 8941399] |
| MCF7 | IC50 |
0.32 nM
Compound: estradiol
|
Effect on estradiol-stimulated MCF-7 cell proliferation
Effect on estradiol-stimulated MCF-7 cell proliferation
|
[PMID: 8941399] |
| MCF7 | EC50 |
1.8 x 10-10 M
Compound: estradiol
|
Affinity for estrogen receptor of human MCF-7 cells
Affinity for estrogen receptor of human MCF-7 cells
|
[PMID: 9371241] |
| MDA-MB-231 | IC50 |
>100 μM
Compound: estradiol
|
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
Inhibitory concentration against MDA-MB-231 (ER-) cell line using SRB assay
|
[PMID: 12565971] |
| MDA-MB-231 | IC50 |
33.46 μM
Compound: ES
|
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
Antiproliferative activity human ER-negative MDA-MB-231 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| MIA PaCa-2 | IC50 |
42.93 μM
Compound: ES
|
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
Antiproliferative activity human MIAPaCa2 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| NIH3T3 | IC50 |
>100 μM
Compound: ES
|
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
Antiproliferative activity mouse NIH/3T3 cells after 2 days by MTT assay
|
[PMID: 25222876] |
| SAOS-2 | ED50 |
4.7 nM
Compound: 2
|
Functional Estrogen receptor beta activity by metallothionein induction in SAOS-2 cells
Functional Estrogen receptor beta activity by metallothionein induction in SAOS-2 cells
|
[PMID: 12824043] |
| Sf9 | IC50 |
12.5 nM
Compound: E2
|
Displacement of [3H]17beta-estradiol from human ERalpha expressed in SF9 cells
Displacement of [3H]17beta-estradiol from human ERalpha expressed in SF9 cells
|
[PMID: 19836949] |
| SH-SY5Y | EC50 |
0.1 nM
Compound: 17-beta-estradiol
|
Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta
Agonist activity in transcriptional activation assay in SH-SY5Y neuroblastoma cells expressing Estrogen receptor beta
|
[PMID: 11906280] |
| SK-BR-3 | IC50 |
0.1 nM
Compound: estrogen
|
Inhibition of chemoattractant-induced cell migration of human SK-BR-3 cells after 48 hrs by transwell migration assay
Inhibition of chemoattractant-induced cell migration of human SK-BR-3 cells after 48 hrs by transwell migration assay
|
[PMID: 16520733] |
| T47D | EC50 |
0.07 nM
Compound: 17-beta-E2
|
Agonist effect on transcriptional activation in T47D cells expressing estrogen receptor alpha
Agonist effect on transcriptional activation in T47D cells expressing estrogen receptor alpha
|
[PMID: 12459017] |
| T47D | EC50 |
0.8 nM
Compound: 17-beta-E2
|
Agonist effect on transcriptional activation of T47D cells expressing human estrogen receptor beta
Agonist effect on transcriptional activation of T47D cells expressing human estrogen receptor beta
|
[PMID: 12459017] |
| U2OS | EC50 |
0.019 nM
Compound: estradiol
|
Transcriptional activation of estrogen receptor alpha in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT
Transcriptional activation of estrogen receptor alpha in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT
|
[PMID: 16162002] |
| U2OS | EC50 |
0.098 nM
Compound: estradiol
|
Transcriptional activation of estrogen receptor beta in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT
Transcriptional activation of estrogen receptor beta in U2OS cell using estrogen-regulated luciferase reporter gene plasmid upon incubation for 20-30 mins at RT
|
[PMID: 16162002] |
| U2OS | EC50 |
0.15 nM
Compound: E2, 17beta-E2, estradiol
|
Agonist activity at human ERalpha expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay
Agonist activity at human ERalpha expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay
|
[PMID: 22122563] |
| U2OS | EC50 |
0.4 nM
Compound: E2, 17beta-E2, estradiol
|
Agonist activity at human ERbeta expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay
Agonist activity at human ERbeta expressed in U2OS cells coexpressing pCMX-hSRC3 assessed as luciferase activity after 24 hrs by reporter gene assay
|
[PMID: 22122563] |
| U2OS | EC50 |
0.004 nM
Compound: E2
|
Activation of human ERalpha expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control
Activation of human ERalpha expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control
|
[PMID: 23043242] |
| U2OS | EC50 |
0.01 nM
Compound: E2
|
Activation of human ERbeta expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control
Activation of human ERbeta expressed in human U2-OS cells by luciferase reporter gene assay relative to untreated control
|
[PMID: 23043242] |
Estradiol (10 nM, 7 days) induces neural differentiation and increased neurite branching of human endometrial stem cells (hEnSCs)[1]. Estradiol (17β-estradiol, 10 nM, 7 days) increases the expression of neuron-like cell markers (Tuj-1, nestin and NF-H) in neural-like cells differentiated from hEnSCs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Isolated human endometrial stem cells (hEnSCs) from human endometrial tissue
-
Concentration:10 nM
-
Incubation Time:7 days
-
Result:Increased the number of neurite processes including neural differentiation and neurite branching.
-
Cell Line:Isolated human endometrial stem cells (hEnSCs) from human endometrial tissue
-
Concentration:10 nM
-
Incubation Time:7 days
-
Result:Increased the percentage of neural marker (Tuj-1, nestin and NF-H)-positive cells of 62.2±1.3%, 71.5±4% and 51.2±1.5% respectively.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:FBN-ARO-KO Mice[2]
-
Dosage:1 nM
-
Administration:Treated for the hippocampal slices
-
Result:Rescued long-term potentiation (LTP) amplitude of both male and female mice.
-
Animal Model:FBN-ARO-KO Mice[2]
-
Dosage:0.0167 mg
-
Administration:Alzet minipumps with Estradiol (implanted s.c.), examined 7 days after minipump implantation.
-
Result:Restored hippocampal and cortical E2 levels to 93%, phosphorylation of AKT, ERK and CREB in the hippocampus and cortex to 90-95%, BDNF level to 80-90%, restored both synaptophysin and PSD95 in the forebrain. Rescued the spatial learning and memory defects.
Chemical Information
-
No. CAS 50-28-2
-
Appearance Solid
-
Peso molecular 272.39
-
Fòrmula C18H24O2
-
Color White to off-white
-
SMILES
C[C@@]1([C@H]2O)[C@](CC2)([H])[C@@](CCC3=C4C=CC(O)=C3)([H])[C@]4([H])CC1
-
Synonyms
β-Estradiol; E2; 17β-Estradiol; 17β-Oestradiol
-
Structure Classification
-
Initial Source
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years 4°C 2 years In solvent -80°C 1 year -20°C 6 months
Publications (124)
-
Journal Impact Factor
-
Most Recent
-
Cell Metab
Sensing steroid hormone 17α-hydroxypregnenolone by GPR56 enables protection from ferroptosis-induced liver injury. [Abstract]2024 Nov 5;36(11):2402-2418.e10. PMID: 39389061 -
Bioact Mater
2025 Jul 15:53:240-252. PMID: 40697396 -
Cancer Res
Estrogen Production in Pancreatic Cancer Shapes a Tumor Suppressive Stromal Microenvironment. [Abstract]2025 Nov 19. PMID: 41258799 -
Nat Commun
Harnessing artificial intelligence to identify Bufalin as a molecular glue degrader of estrogen receptor alpha. [Abstract]2025 Aug 22;16(1):7854. PMID: 40846852 -
Bone Res
C/EBPβ dictates postmenopausal FSHβ transcription and blockade of AEP/C/EBPβ pathway alleviates osteoporosis. [Abstract]2026 Mar 17;14(1):31. PMID: 41844581 -
Nat Chem Biol
2022 Nov;18(11):1196-1203. PMID: 35982227 -
Neuro Oncol
A disintegrin and metalloproteinase 22 activates integrin β1 through its disintegrin domain to promote the progression of pituitary adenoma. [Abstract]2024 Jan 5;26(1):137-152. PMID: 37555799 -
Theranostics
Dysfunction of estrogen-related receptor alpha-dependent hepatic VLDL secretion contributes to sex disparity in NAFLD/NASH development. [Abstract]2020 Aug 29;10(24):10874-10891. PMID: 33042259
Estradiol purchased from MedChemExpress. Usage Cited in: Theranostics. 2020 Aug 29;10(24):10874-10891. [Abstract]
Estradiol (E2) (100 nM; 36 h) treatment can enhance the expression of ERRα and VLDL-related genes such as Apob, Mttp and Pla2g12b, whereas the induction is blocked with loss of ERRα in primary hepatocytes.
-
J Adv Res
Dual regulation of phaseol on osteoclast formation and osteoblast differentiation by targeting TAK1 kinase for osteoporosis treatment. [Abstract]2024 Dec 9:S2090-1232(24)00565-4. PMID: 39662728 -
-
Biosens Bioelectron
Split aptamer regulated CRISPR/Cas12a biosensor for 17β-estradiol through a gap-enhanced Raman tags based lateral flow strategy. [Abstract]2022 Nov 1:215:114548. PMID: 35870335 -
Pharmacol Res
Potential synthetic lethality for breast cancer: A selective sirtuin 2 inhibitor combined with a multiple kinase inhibitor sorafenib. [Abstract]2022 Mar:177:106050. PMID: 34973468 -
ACS Cent Sci
An Epigenetic Switch for Sex-Specific Brain Resilience in Stroke: Targeting HDAC2 to Amplify Endogenous Oxytocin Signaling. [Abstract]2026 Mar 25;12(4):497-523. PMID: 42038487 -
Cell Death Dis
2020 Oct 6;11(10):831. PMID: 33024087 -
Genome Biol
Endometrial tumorigenesis involves epigenetic plasticity demarcating non-coding somatic mutations and 3D-genome alterations. [Abstract]2025 May 9;26(1):124. PMID: 40346709 -
Proc Natl Acad Sci U S A
2025 Aug 19;122(33):e2507571122. PMID: 40815626 -
J Cachexia Sarcopenia Muscle
Oestrogen Receptor Alpha in Myocyte Maintains Muscle Regeneration in Duchenne Muscular Dystrophy. [Abstract]2025 Apr;16(2):e13807. PMID: 40258782 -
Proc Natl Acad Sci U S A
Androgen receptors in corticotropin-releasing hormone neurons mediate the sexual dimorphism in restraint-induced thymic atrophy. [Abstract]2025 Mar 25;122(12):e2426107122. PMID: 40106355 -
J Cachexia Sarcopenia Muscle
Nicotinamide Phosphoribosyltransferase Acetylation Mediating Muscle Dysfunction Contributes to Sleep Apnoea in Obesity. [Abstract]2025 Feb;16(1):e13693. PMID: 39901373
Estradiol purchased from MedChemExpress. Usage Cited in: J Cachexia Sarcopenia Muscle. 2025 Feb;16(1):e13693. [Abstract]
Estradiol (E2) (10-100 nM) exhibites an increase in the SIRT1 protein level in C2C12 cells, without significantly affecting the mRNA level.
-
Cell Commun Signal
Increased HERV-E clone 4-1 expression contributes to DNA hypomethylation and IL-17 release from CD4+ T cells via miR-302d/MBD2 in systemic lupus erythematosus. [Abstract]2019 Aug 14;17(1):94. PMID: 31412880 -
Int J Biol Macromol
Reticuline isomerase AKR1B1 with aldo-keto reductase activity and detoxification function from the insect Blaps rhynchopetera. [Abstract]2026 Mar:352:151224. PMID: 41791543 -
Int J Biol Macromol
Estrogen-mediated oar-miR-485-5p targets PPP1R13B to regulate myoblast proliferation in sheep. [Abstract]2023 May 1:236:123987. PMID: 36906210
Estradiol purchased from MedChemExpress. Usage Cited in: Int J Biol Macromol. 2023 May 1:236:123987. [Abstract]
Estradiol (1-100 nM; 6-72 h) promotes the proliferation of sheep myoblasts.
-
Phytomedicine
Kaempferol targets Src to exert its chemopreventive effects on mammary tumorigenesis via regulation of the PI3K/AKT pathway. [Abstract]2025 Jun:141:156701. PMID: 40220416 -
Phytomedicine
Glycyrol alleviates osteoporosis through dual modulation on osteoclastogenesis and osteogenesis by targeting Syk signaling pathway. [Abstract]2025 Mar:138:156429. PMID: 39939034 -
Phytomedicine
Dihydrotanshinone I targets ESR1 to induce DNA double-strand breaks and proliferation inhibition in hepatocellular carcinoma. [Abstract]2024 Jul 25:130:155767. PMID: 38833789 -
Phytomedicine
Paeonol ameliorates endometrial hyperplasia in mice via inhibiting PI3K/AKT pathway-related ferroptosis. [Abstract]2023 Jan:109:154593. PMID: 36610113 -
Free Radic Biol Med
17β-estradiol plays the anti-osteoporosis role via a novel ESR1-Keap1-Nrf2 axis-mediated stress response activation and Tmem119 upregulation. [Abstract]2023 Feb 1:195:231-244. PMID: 36592659 -
Chemosphere
Early pregnancy exposure to Microcystin-LR compromises endometrial decidualization in mice via the PI3K/AKT/FOXO1 signaling pathway. [Abstract]2024 Oct:366:143466. PMID: 39369752 -
Sci Total Environ
Insights into the role of FoxL2 in tebuconazole-induced male- biased sex differentiation of zebrafish. [Abstract]2024 Jul 6:947:174543. PMID: 38977095
Estradiol purchased from MedChemExpress. Usage Cited in: Sci Total Environ. 2024 Jul 6:947:174543. [Abstract]
Estradiol (E2) (1 μM, 8 h) alone or in combination with TEB (100 μM, 8 h) (TEB + E2) significantly increases the protein expression levels of FoxL2 and pFoxL2 (Ser238) in ZF4 cells.
-
Sci Total Environ
Integrated toxicity of secondary, tertiary, wetland effluents on human stem cells triggered by ERα and PPARγ agonists. [Abstract]2024 May 25:173419. PMID: 38802024 -
NPJ Breast Cancer
Estrogen receptor inhibition mediates radiosensitization of ER-positive breast cancer models. [Abstract]2022 Mar 10;8(1):31. PMID: 35273179 -
J Transl Med
Pleiotrophin modulates cell proliferation, prostate smooth muscle contraction and fibrosis in hyperplastic prostate. [Abstract]2025 Oct 17;23(1):1128. PMID: 41107820 -
Biomed Pharmacother
Chemopreventive effects of atractylenolide-III on mammary tumorigenesis via activation of the Nrf2/ARE pathway through autophagic degradation of Keap1. [Abstract]2024 Jun 3:176:116852. PMID: 38834007 -
J Transl Med
Identification and functional activity of Nik related kinase (NRK) in benign hyperplastic prostate. [Abstract]2024 Mar 9;22(1):255. PMID: 38459501 -
Biomed Pharmacother
Coupling the near-infrared fluorescent dye IR-780 with cabazitaxel makes renal cell carcinoma chemotherapy possible. [Abstract]2019 Aug:116:109001. PMID: 31146114 -
Environ Pollut
Benzophenone-1 induced aberrant proliferation and metastasis of ovarian cancer cells via activated ERα and Wnt/β-catenin signaling pathways. [Abstract]2022 Jan 1;292(Pt B):118370. PMID: 34656677 -
Environ Pollut
Screening of potential oestrogen receptor α agonists in pesticides via in silico, in vitro and in vivo methods. [Abstract]2021 Feb 1;270:116015. PMID: 33352482
Estradiol purchased from MedChemExpress. Usage Cited in: Environ Pollut. 2021 Feb 1;270:116015. [Abstract]
Estradiol (1-10 nM; 24 h) significantly induces mRNA expression of both pS2 and NRF1 genes in MCF-7 cells.
-
Aging Cell
Senescence-Driven Remodeling Defines an Aggressive and Immunomodulatory Subtype of Endometriosis. [Abstract]2026 Apr;25(4):e70463. PMID: 41891132 -
Aging Cell
2024 Aug 7:e14303. PMID: 39113346
Estradiol purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 7:e14303. [Abstract]
Estradiol (3-25 ng/mouse; s.c.; for 7 consecutive days) significantly decreases LAMIN A levels while increasing PROGERIN and PRELAMIN A levels in the uteri of mice injected with 10 ng or 25 ng, compared to those receiving the 3 ng dose.
-
J Med Chem
Discovery of the First-In-Class HSD17B13/PPAR Multitarget Modulators for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis. [Abstract]2025 Oct 15. PMID: 41088966 -
J Med Chem
Discovery of Highly Potent, Selective, and Liver-Targeting HSD17B13 Inhibitor with Robust In Vivo Anti-MASH Activity. [Abstract]2025 Jun 12;68(11):11127-11148. PMID: 40387207 -
J Med Chem
Discovery of First-in-Class FXR and HSD17B13 Dual Modulator for the Treatment of Metabolic Dysfunction-Associated Fatty Liver Disease. [Abstract]2025 Mar 27;68(6):6127-6148. PMID: 39851255 -
Br J Cancer
Androgen and oestrogen receptor co-expression determines the efficacy of hormone receptor-mediated radiosensitisation in breast cancer. [Abstract]2022 Sep;127(5):927-936. PMID: 35618789 -
J Med Chem
Activators of the Anticipatory Unfolded Protein Response with Enhanced Selectivity for Estrogen Receptor Positive Breast Cancer. [Abstract]2022 Mar 10;65(5):3894-3912. PMID: 35080871 -
Anal Chem
High-Throughput Reactive Desorption Electrospray Ionization Mass Spectrometry for Targeted Derivatization and Analysis of Poorly Ionized Small Molecules. [Abstract]2026 Jun 16;98(23):16962-16970. PMID: 42223360 -
NPJ Regen Med
Macrophages maintain mammary stem cell activity and mammary homeostasis via TNF-α-PI3K-Cdk1/Cyclin B1 axis. [Abstract]2023 May 2;8(1):23. PMID: 37130846 -
J Anim Sci Biotechnol
Cysteine dioxygenase and taurine are essential for embryo implantation by involving in E2-ERα and P4-PR signaling in mouse. [Abstract]2023 Jan 5;14(1):6. PMID: 36604722 -
Mol Med
A novel mechanism of FTO modulating the progression of endometriosis through mediating the m6A methylation of GEF-H1 in a YTHDF1-dependent manner. [Abstract]2025 Feb 25;31(1):78. PMID: 40000966 -
Phytother Res
Identification of Sinigrin as Active Compound of Rape Pollen for Treating Benign Prostatic Hyperplasia Through PI3K/AKT/mTOR Axis. [Abstract]2025 May 8. PMID: 40343383 -
Cell Mol Life Sci
Upregulated YTHDC1 mediates trophoblastic dysfunction inducing preterm birth in ART conceptions through enhanced RPL37 translation. [Abstract]2024 Dec 27;82(1):17. PMID: 39725796 -
Hum Reprod
Harmine inhibits oxidative phosphorylation, thus regulating the polarization of macrophages mediated by extracellular adenosine in endometriosis. [Abstract]2025 Jul 29:deaf130. PMID: 40730246 -
JCI Insight
Dynamic transcriptome analysis of osteal macrophages identifies a distinct subset with senescence features in experimental osteoporosis. [Abstract]2024 Oct 31:e182418. PMID: 39480497 -
Ecotoxicol Environ Saf
Impaired GPX4 activity elicits ferroptosis in alveolar type II cells promoting PHMG-induced pulmonary fibrosis development. [Abstract]2024 Jul 2:281:116680. PMID: 38964057 -
Hum Reprod
2019 May 1;34(5):804-812. PMID: 30989213 -
Biochem Pharmacol
Mutant NPM1-regulated estrogen signaling promotes leukemia cell survival by upregulating HGF and represents a therapeutic vulnerability. [Abstract]2026 May:247:117796. PMID: 41679667 -
Biochem Pharmacol
Estradiol alleviated chemotherapy-induced premature ovarian failure by blocking the ferroptosis via activating ESR2/Sirt1/Nrf2 pathway. [Abstract]2025 Oct 29;243(Pt 1):117481. PMID: 41173058 -
Biochem Pharmacol
Sex differences in the metabolic activation of and platelet response to vicagrel in mice: Androgen as a key player. [Abstract]2024 Dec;230(Pt 1):116564. PMID: 39366431 -
Genome Res
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions. [Abstract]2024 May 15;34(4):539-555. PMID: 38719469 -
Pain
Difference of pain vulnerability in adult and juvenile rodents: the role of SIRT1-mediated ClC-3 trafficking in sensory neurons. [Abstract]2021 Jun 1;162(6):1882-1896. PMID: 33433144 -
J Ethnopharmacol
Podophyllum hexandrum Royle mitigates perimenopausal symptoms in an OVX rat model by activating the PI3K/AKT/mTOR pathway and enhancing estrogen receptor expression. [Abstract]2025 May 10:119968. PMID: 40354838 -
J Ethnopharmacol
Guizhi Fuling Capsule ameliorates endometrial hyperplasia through promoting p62-Keap1-NRF2-mediated ferroptosis. [Abstract]2021 Jun 28:274:114064. PMID: 33771639 -
Mol Ther Oncolytics
Berberine inhibits carcinogenesis through antagonizing the ATX-LPA-LPAR2-p38-leptin axis in a mouse hepatoma model. [Abstract]2022 Aug 5:26:372-386. PMID: 36090480 -
Cells
Identification of Resistance Genes in Breast Cancer Cells Treated with Fulvestrant and Ribociclib via Retroviral Screening and Integration Site Sequencing. [Abstract]2026 Jan 29;15(3):260. PMID: 41677624 -
J Clin Endocrinol Metab
2021 Apr 23;106(5):1410-1426. PMID: 33524147 -
Inflammation
Large Peritoneal Macrophages Promote the Resolution of Inflammation in Injured Endometrium. [Abstract]2025 Aug 2. PMID: 40751779 -
-
Int J Mol Sci
Stearoyl-CoA Desaturases1 Accelerates Non-Small Cell Lung Cancer Metastasis by Promoting Aromatase Expression to Improve Estrogen Synthesis. [Abstract]2023 Apr 6;24(7):6826. PMID: 37047797 -
Int Immunopharmacol
2025 Aug 19:164:115392. PMID: 40834530 -
Int Immunopharmacol
Estrogen deficiency promotes neurodegeneration in female hemi-parkinsonian mice: The role of regulatory T cells. [Abstract]2025 Jan 24:148:114104. PMID: 39862633 -
Int Immunopharmacol
CHS-Ⅳa activates the IGF1R/PI3K signal pathway with inhibited pyroptosis of endometrial stromal cells and progress of endometriosis. [Abstract]2024 Nov 2;143(Pt 3):113527. PMID: 39488924 -
Int Immunopharmacol
Pirfenidone inhibits CCL2-mediated Treg chemotaxis induced by palbociclib and fulvestrant in HR+/HER2- breast cancer. [Abstract]2024 Sep 5;142(Pt A):113059. PMID: 39241517 -
Eur J Pharmacol
Onc201 reduces osteoclastogenesis and prevents ovariectomy-induced bone loss via inhibiting RANKL-induced NFATc1 activation and the integrin signaling pathway. [Abstract]2022 May 15;923:174908. PMID: 35405113 -
Int Immunopharmacol
Estrogen facilitates gastric cancer cell proliferation and invasion through promoting the secretion of interleukin-6 by cancer-associated fibroblasts. [Abstract]2020 Jan;78:105937. PMID: 31753587 -
Neuropharmacology
Dyadic social interaction paradigm reveals selective role of ovarian estrogen in the caring behavior and socially transferred pain in female mice. [Abstract]2024 Sep 5:110138. PMID: 39244013 -
Molecules
Identification of Estradiol Benzoate as an Inhibitor of HBx Using Inducible Stably Transfected HepG2 Cells Expressing HiBiT Tagged HBx. [Abstract]2022 Aug 6;27(15):5000. PMID: 35956950 -
Cell Rep Methods
RECOVER identifies synergistic drug combinations in vitro through sequential model optimization. [Abstract]2023 Oct 23;3(10):100599. PMID: 37797618 -
Cancers (Basel)
2024 Feb 9;16(4):726. PMID: 38398117 -
Poult Sci
Research note: Unveiling the impact of ovotransferrin on chicken primordial germ cells biological processes. [Abstract]2025 May 3;104(7):105259. PMID: 40359719 -
Biochim Biophys Acta Mol Basis Dis
USP46 enhances tamoxifen resistance in breast cancer cells by stabilizing PTBP1 to facilitate glycolysis. [Abstract]2024 Mar;1870(3):167011. PMID: 38176460 -
J Cell Mol Med
Tamoxifen inhibits cell proliferation by impaired glucose metabolism in gallbladder cancer. [Abstract]2020 Jan;24(2):1599-1613. PMID: 31782270 -
Sci Rep
A degrader of HER2 and EGFR abolishes p95HER2 and shows robust antitumor efficacy in HER2-positive breast cancer. [Abstract]2026 Apr 20;16(1):12890. PMID: 42009845 -
Sci Rep
Estrogen regulates duodenal calcium absorption and improves postmenopausal osteoporosis by the effect of ERβ on PMCA1b. [Abstract]2025 May 8;15(1):16053. PMID: 40341576 -
Sci Rep
Comparative analysis of organoid, air-liquid interface, and direct infection models for studying pathogen-host interactions in endometrial tissue. [Abstract]2025 Mar 12;15(1):8531. PMID: 40075187 -
Cell Signal
Estradiol alleviates disease phenotypes caused by m.3635G > a mutations by activating mitochondrial biogenesis and PINK1-Parkin mediated mitophagy in iPSC-derived retinal pigment epithelium cells. [Abstract]2025 Sep 8:136:112121. PMID: 40930474 -
Cell Signal
Inhibitory effects of Eplerenone on angiogenesis via modulating SGK1/TGF-β pathway in contralateral kidney of CKD pregnancy rats. [Abstract]2024 Aug 13:111346. PMID: 39147296 -
-
Neurobiol Stress
A sex-dependent delayed maturation of visual plasticity induced by adverse experiences in early childhood. [Abstract]2020 Oct 14;13:100256. PMID: 33344711 -
Mol Hum Reprod
2025 Jul 3;31(3):gaaf037. PMID: 40714816 -
Mol Med Rep
Estrogen inhibits TGF‑β1‑stimulated cardiac fibroblast differentiation and collagen synthesis by promoting Cdc42. [Abstract]2024 Jul;30(1):123. PMID: 38785153 -
Food Chem Toxicol
Gestational cadmium exposure disrupts fetal liver development via repressing estrogen biosynthesis in placental trophoblasts. [Abstract]2023 Jun:176:113807. PMID: 37121429 -
BMC Cancer
Immune characteristics analysis and construction of a four-gene prognostic signature for lung adenocarcinoma based on estrogen reactivity. [Abstract]2023 Oct 31;23(1):1047. PMID: 37907850 -
Life Metab
Intestinal monocarboxylate transporter 1 mediates lactate transport in the gut and regulates metabolic homeostasis of mouse in a sex-dimorphic pattern. [Abstract]2023 Nov 6;3(1):load041. PMID: 39871878 -
Naunyn Schmiedebergs Arch Pharmacol
Andrographolide blocked the progression of endometriosis by promoting ferroptosis via inhibiting anabolism of serine. [Abstract]2025 Dec 18. PMID: 41408483 -
Mol Reprod Dev
Decreased OGT Attenuates Endometrial Decidualization and Embryo Implantation by Affecting HIF-1α Stability. [Abstract]2025 May;92(5):e70025. PMID: 40342239 -
Genomics
2025 Jan 21;117(2):111002. PMID: 39848478 -
Breast Cancer Res Treat
Monopolar spindle 1 contributes to tamoxifen resistance in breast cancer through phosphorylation of estrogen receptor α. [Abstract]2023 Dec;202(3):595-606. PMID: 37695401 -
Biol Reprod
G protein-coupled estrogen receptor promotes acrosome reaction via regulation of Ca2+ signaling in mouse sperm. [Abstract]2022 Oct 11;107(4):1026-1034. PMID: 35774023 -
J Pharmacol Sci
Gallic acid ameliorates endometrial hyperplasia through the inhibition of the PI3K/AKT pathway and the down-regulation of cyclin D1 expression. [Abstract]2024 May;155(1):1-13. PMID: 38553133 -
Genes (Basel)
Effect of Exogenous Hormone on R-Spondin 2 (Rspo2) and R-Spondin 3 (Rspo3) Gene Expression and Embryo Development in Chinese Soft-Shelled Turtle (Pelodiscus sinensis). [Abstract]2023 Jul 19;14(7):1466. PMID: 37510371 -
Front Genet
Genome-wide analysis of the FOXA1 transcriptional regulatory network identifies super enhancer associated LncRNAs in tamoxifen resistance. [Abstract]2022 Sep 20:13:992444. PMID: 36204307 -
J Assist Reprod Genet
High concentration of estrogen resulted by COH may affect the secretion of pro-angiogenic factors in uNK cells by downregulating the expression of IL-11 in decidual stromal cells. [Abstract]2024 Nov;41(11):3189-3200. PMID: 39276273 -
PLoS One
Estrogen protects against liver damage in sepsis through inhibiting oxidative stress mediated activation of pyroptosis signaling pathway. [Abstract]2020 Oct 1;15(10):e0239659. PMID: 33002070 -
J Steroid Biochem Mol Biol
Integrin αVβ3 mediates estrogen to enhance osteoblast proliferation, differentiation, and alleviate OVX-induced postmenopausal osteoporosis. [Abstract]2025 Jun 2:106800. PMID: 40466876 -
-
Gene
Sequences analysis and pituitary actions of tachykinins in Chinese sturgeon (Acipenser sinensis). [Abstract]2023 Aug 30:879:147592. PMID: 37356741 -
-
Steroids
Exploration of interaction property between nonylphenol and G protein-coupled receptor 30 based on molecular simulation and biological experiments. [Abstract]2022 Dec:188:109114. PMID: 36154832 -
Biochem Biophys Res Commun
Estrogen deficiency impairs double-negative T cell function and activates NF-κB in postmenopausal osteoporosis. [Abstract]2025 Jun 14:776:152212. PMID: 40532308 -
Biochem Biophys Res Commun
Mitochondrial calcium homeostasis mediated by estradiol contributes to atrial fibrillation protection. [Abstract]2025 May 20:772:152050. PMID: 40414005 -
Physiol Rep
Estrogen-dependent gene regulation: Molecular basis of TIMP-1 as a sex-specific biomarker for acute lung injury. [Abstract]2024 Sep;12(17):e70047. PMID: 39267201 -
Zygote
2022 Jun;30(3):330-337. PMID: 34704551 -
-
-
-
-
-
-
bioRxiv
Breast cancer risk SNPs converge on estrogen receptor binding sites commonly shared between breast tumors to locally alter estrogen signalling output. [Abstract]2023 Nov 2:2023.10.30.564691. PMID: 37961147 -
-
-
-
-
-
Res Sq
Sex differences in viral entry protein expression, host responses to SARS-CoV-2, and in vitro responses to sex steroid hormone treatment in COVID-19. [Abstract]2020 Dec 31:rs.3.rs-100914. PMID: 33173861
Solvente y solubilidad
DMSO : 100 mg/mL (367.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Ethanol : 16.67 mg/mL (61.20 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.18 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.64 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: Corn Oil
Solubility: 12.5 mg/mL (45.89 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (623 KB)
- English - EN (623 KB)
- Français - FR (623 KB)
- Deutsch - DE (623 KB)
- Norwegian - NO (623 KB)
- Español - ES (623 KB)
- Swedish - SV (623 KB)
- Italian - IT (623 KB)
- Portuguese - PT (623 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Elham Hasanzadeh. Defining the role of 17β-estradiol in human endometrial stem cells differentiation into neuron-like cells. Cell Biol Int. 2021 Jan;45(1):140-153. [Content Brief]
[2]. Yujiao Lu, et al. Neuron-Derived Estrogen Regulates Synaptic Plasticity and Memory. J Neurosci. 2019 Apr 10;39(15):2792-2809. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| Ethanol / DMSO | 1 mM | 3.6712 mL | 18.3560 mL | 36.7121 mL | 91.7802 mL |
| 5 mM | 0.7342 mL | 3.6712 mL | 7.3424 mL | 18.3560 mL | |
| 10 mM | 0.3671 mL | 1.8356 mL | 3.6712 mL | 9.1780 mL | |
| 15 mM | 0.2447 mL | 1.2237 mL | 2.4475 mL | 6.1187 mL | |
| 20 mM | 0.1836 mL | 0.9178 mL | 1.8356 mL | 4.5890 mL | |
| 25 mM | 0.1468 mL | 0.7342 mL | 1.4685 mL | 3.6712 mL | |
| 30 mM | 0.1224 mL | 0.6119 mL | 1.2237 mL | 3.0593 mL | |
| 40 mM | 0.0918 mL | 0.4589 mL | 0.9178 mL | 2.2945 mL | |
| 50 mM | 0.0734 mL | 0.3671 mL | 0.7342 mL | 1.8356 mL | |
| 60 mM | 0.0612 mL | 0.3059 mL | 0.6119 mL | 1.5297 mL | |
| DMSO | 80 mM | 0.0459 mL | 0.2295 mL | 0.4589 mL | 1.1473 mL |
| 100 mM | 0.0367 mL | 0.1836 mL | 0.3671 mL | 0.9178 mL |